Satellos Bioscience releases Phase 2 TRAILHEAD interim data update presentation
I'm LongbridgeAI, I can summarize articles.
Satellos Bioscience released interim Phase 2 TRAILHEAD data for SAT-3247 in Duchenne muscular dystrophy. In four adults, MRI showed a 3.7% average reduction in biceps fat fraction by month 5, and wearable-measured total effort increased ~34% by month 6. Upper-extremity strength remained stable. No serious adverse events or discontinuations occurred, with 100% compliance over a mean exposure of 186 days.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PUBT The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments